TY - JOUR
T1 - Progressive reduction of auditory evoked gamma in first episode schizophrenia but not clinical high risk individuals
AU - Oribe, Naoya
AU - Hirano, Yoji
AU - del Re, Elisabetta
AU - Seidman, Larry J.
AU - Mesholam-Gately, Raquelle I.
AU - Woodberry, Kristen A.
AU - Wojcik, Joanne D.
AU - Ueno, Takefumi
AU - Kanba, Shigenobu
AU - Onitsuka, Toshiaki
AU - Shenton, Martha E.
AU - Goldstein, Jill M.
AU - Niznikiewicz, Margaret A.
AU - McCarley, Robert W.
AU - Spencer, Kevin M.
N1 - Funding Information:
This work was supported by the U.S. Department of Veterans Affairs ( CX000154 to K.M.S.); National Institute of Mental Health ( K05MH070047 and R01MH50747 to M.E.S., R01MH40799 and R01MH052807 to R.W.M., CIDAR P50MH080272 to R.W.M., R01MH080187 and R01MH093450 to K.M.S.); the Commonwealth Research Center of the Massachusetts Department of Mental Health ( SCDMH82101008006 to L.J.S.); Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation S2208 (S.K. and T.O.) and Grant-in-Aid for Young Scientists B 22791129 (Y.H.), 15K19735 (N.O.) from the Japan Society for the Promotion of Science ; the Fund for Pharmacopsychiatry Research from the Senshin Medical Research Foundation (Y.H.).
Funding Information:
We thank all participants who participated in the study, and T. Tasoff and K. D. Kim for their support as research assistants. We also thank the clinical, research, and data management staff from the Boston CIDAR study, including Ann Cousins, PhD, APRN; Michelle Friedman-Yakoobian, PhD; Anthony J. Giuliano, PhD; Matcheri Keshavan, MD; Janine Rodenhiser-Hill, PhD; Andr?a Gnong-Granato, MSW; Lauren Gibson, EdM; Sarah Hornbach, BA; Julia Schutt, BA; Kristy Klein, PhD; Maria Hiraldo, PhD; Grace Francis, PhD; Corin Pilo, LMHC; Rachael Serur, BS; Reka Szent-Imry, BA; Shannon Sorenson, BA; Grace Min, EdM; Alison Thomas, BA; Chelsea Wakeham, BA; Caitlin Bryant, BS; and Molly Franz, BA. Finally, we are grateful for the hard work of many research volunteers, including Zach Feder, Elizabeth Piazza, Julia Reading, Devin Donohoe, Sylvia Khromina, Alexandra Oldershaw, and Olivia Schanz. This work was supported by the U.S. Department of Veterans Affairs (CX000154 to K.M.S.); National Institute of Mental Health (K05MH070047 and R01MH50747 to M.E.S. R01MH40799 and R01MH052807 to R.W.M. CIDAR P50MH080272 to R.W.M. R01MH080187 and R01MH093450 to K.M.S.); the Commonwealth Research Center of the Massachusetts Department of Mental Health (SCDMH82101008006 to L.J.S.); Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation S2208 (S.K. and T.O.) and Grant-in-Aid for Young Scientists B 22791129 (Y.H.), 15K19735 (N.O.) from the Japan Society for the Promotion of Science; the Fund for Pharmacopsychiatry Research from the Senshin Medical Research Foundation (Y.H.).
Publisher Copyright:
© 2019
PY - 2019/6
Y1 - 2019/6
N2 - The early auditory-evoked gamma band response (EAGBR) may serve as an index of the integrity of fast recurrent inhibition or synaptic connectivity in the auditory cortex, where abnormalities in individuals with schizophrenia have been consistently found. The EAGBR has been rarely investigated in first episode schizophrenia patients (FESZ) and individuals at clinical high risk (CHR) for schizophrenia, and never been compared directly between these populations nor evaluated longitudinally. Here we examined the EAGBR in FESZ, CHR, and matched healthy controls (HC) at baseline and 1-year follow-up assessments to determine whether the EAGBR was affected in these clinical groups, and whether any EAGBR abnormalities changed over time. The electroencephalogram was recorded with a dense electrode array while subjects (18 FESZ, 18 CHR, and 40 HC) performed an auditory oddball task. Event-related spectral measures (phase locking factor [PLF] and evoked power) were computed on Morlet-wavelet-transformed single epochs from the standard trials. At baseline, EAGBR PLF and evoked power did not differ between groups. FESZ showed progressive reductions of PLF and evoked power from baseline to follow-up, and deficits in PLF at follow-up compared to HC. EAGBR peak frequency also increased at temporal sites in FESZ from baseline to follow-up. Longitudinal effects on the EAGBR were not found in CHR or HC, nor did these groups differ at follow-up. In conclusion, we detected neurophysiological changes of auditory cortex function in FESZ during a one-year period, which were not observed in CHR. These findings are discussed within the context of neurodevelopmental models of schizophrenia.
AB - The early auditory-evoked gamma band response (EAGBR) may serve as an index of the integrity of fast recurrent inhibition or synaptic connectivity in the auditory cortex, where abnormalities in individuals with schizophrenia have been consistently found. The EAGBR has been rarely investigated in first episode schizophrenia patients (FESZ) and individuals at clinical high risk (CHR) for schizophrenia, and never been compared directly between these populations nor evaluated longitudinally. Here we examined the EAGBR in FESZ, CHR, and matched healthy controls (HC) at baseline and 1-year follow-up assessments to determine whether the EAGBR was affected in these clinical groups, and whether any EAGBR abnormalities changed over time. The electroencephalogram was recorded with a dense electrode array while subjects (18 FESZ, 18 CHR, and 40 HC) performed an auditory oddball task. Event-related spectral measures (phase locking factor [PLF] and evoked power) were computed on Morlet-wavelet-transformed single epochs from the standard trials. At baseline, EAGBR PLF and evoked power did not differ between groups. FESZ showed progressive reductions of PLF and evoked power from baseline to follow-up, and deficits in PLF at follow-up compared to HC. EAGBR peak frequency also increased at temporal sites in FESZ from baseline to follow-up. Longitudinal effects on the EAGBR were not found in CHR or HC, nor did these groups differ at follow-up. In conclusion, we detected neurophysiological changes of auditory cortex function in FESZ during a one-year period, which were not observed in CHR. These findings are discussed within the context of neurodevelopmental models of schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=85064314995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064314995&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2019.03.025
DO - 10.1016/j.schres.2019.03.025
M3 - Article
C2 - 31005464
AN - SCOPUS:85064314995
SN - 0920-9964
VL - 208
SP - 145
EP - 152
JO - Schizophrenia research
JF - Schizophrenia research
ER -